PTGX vs RVTY
Protagonist Therapeutics, Inc. vs Revvity — AI-powered side-by-side comparison
PTGX
Protagonist Therapeutics, Inc.
70
Buy
VS
| Metric | PTGX | RVTY |
|---|
| AI Score |
70
|
75
|
| Price |
$155.12
|
$116.77
|
| P/E Ratio |
127.33×
|
55.64×
|
| ROE |
-21.2%
|
3.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.9%
|
52.1%
|
| Debt / Equity |
0.01×
|
0.46×
|
| Dividend Yield |
0.0%
|
0.2%
|
| RSI (14) |
75.9
|
65.1
|
| Beta |
1.794
|
1.072
|
| Expected Upside |
—
|
+1.3%
|
AI Committee View
Current Innellis committee reasoning for PTGX versus RVTY.
RVTY leads by 5 points.
RVTY scores 75/100 (Buy) versus PTGX at 70/100 (Buy).
PTGX Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Weekly RSI at 87 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 20.7% signals elevated volatility — Risk
RVTY Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is sector concentration is already high (hhi 2971.31). The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Stochastic RSI (92.1) confirms overbought conditions.
- Risk/reward is unfavorable: 28.5% downside vs 1.3% upside.